Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) is set to post its quarterly earnings results before the market opens on Wednesday, May 4th. Analysts expect Deciphera Pharmaceuticals to post earnings of ($0.83) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last announced its quarterly earnings results on Tuesday, February 8th. The company reported ($1.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.49) by ($0.02). The firm had revenue of $24.20 million for the quarter, compared to analyst estimates of $23.28 million. Deciphera Pharmaceuticals had a negative net margin of 306.78% and a negative return on equity of 72.17%. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.10) earnings per share. On average, analysts expect Deciphera Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Deciphera Pharmaceuticals stock traded down $0.27 during trading on Tuesday, hitting $10.64. 8,983 shares of the stock traded hands, compared to its average volume of 1,324,341. The company has a market capitalization of $622.97 million, a PE ratio of -2.07 and a beta of 1.41. Deciphera Pharmaceuticals has a twelve month low of $6.51 and a twelve month high of $11.85. The business’s fifty day moving average is $9.20.
In related news, major shareholder Brightstar Associates Llc bought 1,478,978 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Friday, April 29th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $14,789,780.00. Following the acquisition, the insider now owns 18,051,348 shares in the company, valued at $180,513,480. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders sold 3,718 shares of company stock valued at $33,648. Corporate insiders own 4.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank bought a new position in Deciphera Pharmaceuticals in the 4th quarter worth approximately $3,596,000. Barclays PLC increased its position in Deciphera Pharmaceuticals by 120.6% in the 4th quarter. Barclays PLC now owns 140,283 shares of the company’s stock worth $1,371,000 after buying an additional 76,704 shares during the period. BlackRock Inc. increased its position in Deciphera Pharmaceuticals by 2.8% in the 4th quarter. BlackRock Inc. now owns 3,797,569 shares of the company’s stock worth $37,102,000 after buying an additional 102,664 shares during the period. Goldman Sachs Group Inc. increased its position in Deciphera Pharmaceuticals by 739.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,635,510 shares of the company’s stock worth $35,519,000 after buying an additional 3,202,527 shares during the period. Finally, California State Teachers Retirement System increased its position in Deciphera Pharmaceuticals by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 55,595 shares of the company’s stock worth $543,000 after buying an additional 1,187 shares during the period. 87.97% of the stock is currently owned by institutional investors.
Deciphera Pharmaceuticals Company Profile (Get Rating)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- Another Buy The Dip Opportunity In Freshpet
- Inflation Wreaks Havoc On Haverty Furniture Company
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- GitLab Stock is Trying to Put in a Bottom Here
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.